-
11.发明申请CALCIUM FLUX AS A PHARMACOEFFICACY BIOMARKER FOR INHIBITORS OF HISTONE DEACETYLASE 审中-公开钙通道作为药物脱乙酰壳多糖抑制剂的药物生物标志物
公开(公告)号：WO2008128093A1
公开(公告)日：2008-10-23
申请号：PCT/US2008/060098
申请日：2008-04-11
Applicant: PHARMACYCLICS, INC. , BALASUBRAMANIAN, Sriram , BUGGY, Joseph, J. , RAMOS, Jason , SIRISAWAD, Mint
Inventor： BALASUBRAMANIAN, Sriram , BUGGY, Joseph, J. , RAMOS, Jason , SIRISAWAD, Mint
IPC: A61K38/18
CPC classification number: G01N33/57438 , G01N33/6872 , G01N33/84 , G01N2800/52
Abstract: Described herein are methods for using calcium flux as a biomarker to select and predict patients likely to respond to an apoptotic agent as therapy. Further described herein is a method of using calcium flux as a clinical biomarker to determine whether a tumor is sensitive to an HDAC inhibitor.
Abstract translation: 本文描述了使用钙通量作为生物标志物来选择和预测可能对凋亡剂作出响应的患者作为治疗的方法。 本文进一步描述的是使用钙通量作为临床生物标志物来确定肿瘤是否对HDAC抑制剂敏感的方法。
-
12.发明申请METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS 审中-公开用于确定抗组氨酸脱乙酰酶抑制剂的耐药性的方法
公开(公告)号：WO2008095050A1
公开(公告)日：2008-08-07
申请号：PCT/US2008/052540
申请日：2008-01-30
Applicant: PHARMACYCLICS, INC. , BUGGY, Joseph, J. , BALASUBRAMANIAN, Sriram
Inventor： BUGGY, Joseph, J. , BALASUBRAMANIAN, Sriram
IPC: A61K49/00 , C12Q1/68 , G01N33/574
CPC classification number: C12Q1/6886 , C07H21/04 , C12N5/0693 , C12N15/11 , C12N2503/02 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16 , G01N33/57419 , G01N33/57492 , G01N2800/52
Abstract: [00153] Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are used in conjunction with the aforementioned methods and compositions.
Abstract translation: 本文描述了用于确定特定癌症是否对组蛋白脱乙酰酶抑制剂或组蛋白脱乙酰酶抑制剂具有抗性或易感性的方法和组合物。 所述方法包括分析与对组蛋白脱乙酰酶抑制剂的反应相关的至少四种生物标记基因的表达水平。 本文还描述了用于增加患者治疗有效治疗可能性的方法和组合物，包括与对组蛋白脱乙酰酶抑制剂的反应相关的至少四种生物标记基因的表达水平的分析。 本文还描述了衍生自对组蛋白脱乙酰酶抑制剂敏感或抗性的癌症的分离的核酸群体。 进一步描述了与上述方法和组合物结合使用的试剂盒和适应症。
-
13.发明申请USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF T-CELL PROLIFERATIVE DISORDERS 审中-公开HDAC8选择性抑制剂用于治疗T细胞增殖性疾病的用途
公开(公告)号：WO2008060721A1
公开(公告)日：2008-05-22
申请号：PCT/US2007/073802
申请日：2007-07-18
Applicant: PHARMACYCLICS, INC. , BUGGY, Joseph, J. , BALASUBRAMANIAN, Sriram
Inventor： BUGGY, Joseph, J. , BALASUBRAMANIAN, Sriram
IPC: A61K31/535
CPC classification number: C12Q1/34 , A61K31/535 , G01N33/57426 , G01N2333/918 , G01N2800/52
Abstract: Described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8. Also described herein are methods for treating a subject suffering from a T-cell lymphoma by administering to the subject a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo .
Abstract translation: 本文描述的是通过向受试者施用含有治疗有效量的组蛋白脱乙酰酶8的选择性抑制剂的药物组合物来治疗患有T细胞淋巴瘤的受试者的方法。本文还描述了治疗患有T细胞的受试者的方法 细胞淋巴瘤，其通过向受试者施用已经离体地暴露于选择性HDAC8抑制剂组合物的自体T细胞群体。
-
14.发明公开SCHEMA D'ADMINISTRATION DU N- HYDROXY - 4 - {2- [3- (N, N- DIMETHYLAMINOMETHYL) BENZOFURAN- 2 - YLCARBONYLAMINO]ETHOXY} BENZAMIDE 有权N-羟基-4- {2- [3-（N，N-二甲基氨基甲基）苯并呋喃-2-基羰基氨基]乙氧基}苯甲酰胺的剂量方案
公开(公告)号：EP2753322A1
公开(公告)日：2014-07-16
申请号：EP12769146.7
申请日：2012-09-07
Applicant: Les Laboratoires Servier , Pharmacyclics, Inc.
Inventor： KLOOS, Ioana , ROBERT, Renata , JACQUET-BESCOND, Anne , DEPIL, Stéphane , CHENEL, Marylore , FOULIARD, Sylvain , BALASUBRAMANIAN, Sriram
IPC: A61K31/138 , A61K31/343 , A61K31/704 , A61K33/24 , A61P35/00
CPC classification number: A61K31/343 , A61K31/138 , A61K31/704 , A61K33/24 , A61N5/10 , A61K2300/00
Abstract: A novel scheme for administering N-hydroxy-4-{2-[3-{N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in combination with a surgical, chemotherapy or hormone therapy treatment or with radiotherapy, for the treatment of cancer, characterized in that it is administered for 4 consecutive days, this period being followed by 3 consecutive days without any administration of the compound of formula (I), wherein it is understood that the chemotherapy treatment is not FOLFOX.
-
公开(公告)号：EP2265590A2
公开(公告)日：2010-12-29
申请号：EP09733489.0
申请日：2009-04-15
Applicant: PHARMACYCLICS, INC.
Inventor： VERNER, Erik , BALASUBRAMANIAN, Sriram , BUGGY, Joseph, J.
IPC: C07D235/06 , C07D235/08 , C07D235/10 , C07D235/12 , C07D235/14
CPC classification number: A61K45/06 , A61K31/40 , A61K31/404 , A61K31/4439 , A61K31/5377 , C07D207/337 , C07D209/08 , C07D209/12 , C07D209/14 , C07D235/06 , C07D307/79 , C07D307/80 , C07D333/54 , C07D333/56 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D471/04 , Y02A50/40
Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
-
Patent Agency Ranking16.发明公开CALCIUM FLUX AS A PHARMACOEFFICACY BIOMARKER FOR INHIBITORS OF HISTONE DEACETYLASE 审中-公开钙通量作为一种药理活性生物标记物用于抑制剂DEACETYLASE
公开(公告)号：EP2144622A1
公开(公告)日：2010-01-20
申请号：EP08745659.6
申请日：2008-04-11
Applicant: PHARMACYCLICS, INC.
Inventor： BALASUBRAMANIAN, Sriram , BUGGY, Joseph, J. , RAMOS, Jason , SIRISAWAD, Mint
IPC: A61K38/18
CPC classification number: G01N33/57438 , G01N33/6872 , G01N33/84 , G01N2800/52
Abstract: Described herein are methods for using calcium flux as a biomarker to select and predict patients likely to respond to an apoptotic agent as therapy. Further described herein is a method of using calcium flux as a clinical biomarker to determine whether a tumor is sensitive to an HDAC inhibitor.
Abstract translation: 本文描述了使用钙通量作为生物标志物以选择和预测可能对作为治疗的凋亡剂作出反应的患者的方法。 本文进一步描述了使用钙通量作为临床生物标志物以确定肿瘤是否对HDAC抑制剂敏感的方法。
-
17.发明授权SCHEMA D'ADMINISTRATION DU N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2-YLCARBONYLAMINO]ETHOXY}BENZAMIDE 有权二苯胺VON N-羟基-4- {2- [3-（N，N-二甲基氨基甲酰基）苯并呋喃-2-基甲基]氨基]
公开(公告)号：EP2753322B1
公开(公告)日：2016-08-03
申请号：EP12769146.7
申请日：2012-09-07
Applicant: Pharmacyclics, Inc.
Inventor： KLOOS, Ioana , ROBERT, Renata , JACQUET-BESCOND, Anne , DEPIL, Stéphane , CHENEL, Marylore , FOULIARD, Sylvain , BALASUBRAMANIAN, Sriram
IPC: A61K31/138 , A61K31/343 , A61K31/704 , A61K33/24 , A61P35/00
CPC classification number: A61K31/343 , A61K31/138 , A61K31/704 , A61K33/24 , A61N5/10 , A61K2300/00
-
18.发明公开COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF 审中-公开组蛋白DEACETYLASEHEMMER组合及其用途和帕唑帕尼
公开(公告)号：EP2814493A2
公开(公告)日：2014-12-24
申请号：EP13748860.7
申请日：2013-02-15
Applicant: Pharmacyclics, Inc.
Inventor： BALASUBRAMANIAN, Sriram , MODY, Tarak, D.
IPC: A61K31/506 , A61K31/517 , A61P35/00
CPC classification number: A61K31/343 , A61K31/506 , A61K45/06 , A61N5/10 , A61K2300/00
-
19.发明公开NOUVELLE ASSOCIATION ENTRE LE N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2-YLCARBONYLAMINO]ETHOXY}BENZAMIDE ET LE FOLFOX 审中-公开新的组合的N-羟基-4- {2- [3-（N，N-二甲基氨基甲基）苯并呋喃-2-基 - 羰基氨基]乙氧基}苯甲酰胺和FOLFOX
公开(公告)号：EP2785704A1
公开(公告)日：2014-10-08
申请号：EP12743494.2
申请日：2012-07-03
Applicant: Les Laboratoires Servier , Pharmacyclics, Inc.
Inventor： DEPIL, Stéphane , JACQUET-BESCOND, Anne , KLOOS, Ioana , SARRY, Anne-Laure , BALASUBRAMANIAN, Sriram , BUGGY, Joseph
IPC: C07D333/70 , C07D405/06 , C07D405/12 , A61K31/19 , A61K31/519 , A61K31/282 , A61K31/505 , A61K35/00
CPC classification number: A61K31/343 , A61K31/19 , A61K31/282 , A61K31/505 , A61K31/513 , A61K31/519 , C07D307/85 , C07D333/70 , C07D405/06 , C07D405/12 , A61K31/424
Abstract: The invention relates to a combination of N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}benzamide with formula (I): or one of the pharmaceutically acceptable base or acid addition salts thereof and FOLFOX for cancer treatment.
-
20.发明公开METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS 审中-公开VERFAHREN ZUR BESTIMMUNG DER KREBSRESSTENZ GEGEN HISTONDEACETYLASEHEMMER
公开(公告)号：EP2993473A1
公开(公告)日：2016-03-09
申请号：EP15172858.1
申请日：2008-01-30
Applicant: Pharmacyclics, Inc.
Inventor： BUGGY, Joseph J. , BALASUBRAMANIAN, Sriram
IPC: G01N33/574
CPC classification number: C12Q1/6886 , C07H21/04 , C12N5/0693 , C12N15/11 , C12N2503/02 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , C12Q2600/16 , G01N33/57419 , G01N33/57492 , G01N2800/52
Abstract: Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are used in conjunction with the aforementioned methods and compositions.
Abstract translation: 本文描述了用于确定特定癌症是否对组蛋白脱乙酰酶抑制剂或组蛋白脱乙酰酶抑制剂具有抗性或易感性的方法和组合物。 所述方法包括分析与对组蛋白脱乙酰酶抑制剂的反应相关的至少四种生物标记基因的表达水平。 本文还描述了用于增加患者治疗有效治疗可能性的方法和组合物，包括与对组蛋白脱乙酰酶抑制剂的反应相关的至少四种生物标记基因的表达水平的分析。 本文还描述了衍生自对组蛋白脱乙酰酶抑制剂敏感或抗性的癌症的分离的核酸群体。 进一步描述了与上述方法和组合物结合使用的试剂盒和适应症。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.038 seconds)
